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Inhibition of protein kinase Cma isoform enhances the
P-glycoprotein expression and the survival of LoVo
human colon adenocarcinoma cells to doxorubicin
exposure
CAM La Porta13, E Dolfini2 and R Comolli3
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Milan. and 3CNR Center for Research in Cell Pathology. Milan. Italy
Summary The aim of the present paper was to analyse the effect of long-term inhibitory treatment, for at least 7 days, of individual protein
kinase C (PKC) isoforms on the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure. The treatment for 2 h, after
plating the cells, and after 3 days with 1 gM Go6976, a specific inhibitor of protein kinase C (PKC)-a and -i1 isoforms, induced on day 7 in
LoVo cell lines (WT) a significant increased survival when these cells were exposed to increasing doxorubicin concentrations. In contrast.
resistant LoVo cells (DX) did not show significant changes in the survival to doxorubicin exposure when incubated with the inhibitor of the
same specific PKC isoforms. In addition, G66976 reduced the PKC-a activity (the main calcium-dependent PKC isoforms expressed) in both
cell lines with contemporary increased expression. Under such conditions. an increased nuclear activity and an increased P-glycoprotein
expression occurred only in WT-treated cells with respect to untreated cells. Taken together, our data indicate a specific relationship between
PKC-a inhibition, the increased nuclear PKC-a activity as well as the increased expression of P-glycoprotein. possibly causing the acquisition
of a resistant phenotype in WT LoVo cells.
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Tumourcells develop drug resistance through multiple mechanisms.
One form ofdrug resistance. termed multidrua resistance' (MDR)
leads to simultaneous cross-resistance to several structurallv unre-
lated natural products. The mechanism 5s1 of resistance is due to an
energx -dependent drug efflux which results in a net decreased intra-
cellular drug accumulation. Malignant mammalian cell lines w-ith
the MDR phenotype may haxe an amplified rndr-I gene or an
increased protein product of the mdr-J cene called P-glycoprotein
(Fine et al. 1996). Numerous papers demonstrated that MDR xwas
associated with many changes in tumour cells. including increased
glutathione peroxidase actixitv. decreased levels and mutations in
DNA topoisomerases. decreased lexvels of cNtochrome P450
enzymes. oxerexpression ofthe anionic isoenzvme ofglutathione-S-
transferase. an altered cell membrane composition and changes in
the expression and actixity of protein kinase C (PKC) isoenzymes
(Endicott and Lina. 1989: O'Brian and Ward. 1989).
In human breast cancer cells. phorbol esters increase PKC
protein lexels as well as the drug resistance in clonogenic assay
(Fine et al. 19881. A number of laboratories have reported an
increased actixvitv and/or amount of PKC in MDR cell lines such
as sarcoma-180 (Posada et al. 1989a). murine fibrosarcoma (Ward
and O Brian. 1991f. P-388 leukaemia (Gallapudi et al. 1992). HL-
60 leukaemia (Aquino et al. 1988). human KB-carcinoma cells
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IPosada et al. 1989b) and murine DCF-3F cells (Palavoor et al.
1987). In Xitro. P-gl-coprotein is phosphon-lated by PKC at serine
residues (Chambers et al. 1993: Orr et al. 19931.
PKC is a familx of at least 11 isotVpes x-hich are classified into
three groups: c-PKC isoforms: ax. PI. PH andy. n-PKC: E. 6. rj. 0. Pi:
a-PKC: '. MA. Differences in expression. substrate specificitx and
actixvator requirements suggest that PKC isoenzvmes may haxe
distinct roles in different signalling pathways (Blobe et al. 1996).
Little is known about the involxement of specific isoforms in the
acquisition of an MDR phenotype. Overexpression of PKC-a
induced an increased MDR phenotype in MCF7 cells (Yu et al.
1991). Recentl, in acute myelogenous leukaemias showinz an MDR
phenotvpe. a positixe correlation between PKC-T and -0 expression
and MDR phenotype has been demonstrated (Beck et al. 1996).
The aim of the present study was to clarifx the role of c-PKC
isoforms in the acquisition of a drug-resistant phenotype. We used
as a model the well-characterized human colon adenocarcinoma
LoVo cell lines sensitixe (OWT) or resistant (DX) to doxorubicin
after continuous exposure to the druc. A prexious paper demon-
strated that VT and DX cells express mainly the PKC-a isoform.
PKC-4 show-ing an actixitv eightfold loxxwer than PKC-ot. PKC-y
beinc undetectable (Dolfini et al. 1993).
In this studv. we demonstrate that long-term inhibition of the
PKC-a isoform x ith G66976. a PKC inhibitor specifically
selected for ax and PI PKC isoforms IFigure 11(Martinx-Baron et
al. 1993). treating these cells for 2 hours after plating and 3 days
later induced on dax 7 in LoVo AXT cells a significant increase in
surxix al x hen exposed to doxorubicin. suggesting a possible
inxolxement of such isoenzyme in the acquisition of a drug-
resistant phenotype.
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Table 1 c-PKC activity (pmol per min per 106 cells)
WT DX
Particulate Cytosol Particulate Cytosol
68±20 32±10 27±4 8±0.5
Go6976 27 ± 12** ND 13 ±5** 8± 1.0
Subconfluent cells were treated with 1 gIM Go6976 for 2 h and after 3 days.
The c-PKC activity was assayed 4 days later. ND = not detected.
**P< 0.01 vs. untreated control.
MATERIALS AND METHODS
Cell culture
The human colon adenocarcinoma WT LoVo cell line (American
Type Culture Collection, Rockville, USA) was grown in vitro in
F12 medium supplemented with 10% fetal calf serum and main-
tained at 370C in a humid atmosphere (5% carbon dioxide-95%
air). DX LoVo cells were isolated after repeated treatment of such
cells with doxorubicin (Grandi et al, 1986).
Inhibition of PKC isoforms
Subconfluent cells were treated with 1 ,UM Go6976 (Calbiochem,
La Jolla, CA, USA) for 2 h. The medium was removed and fresh
medium was added for 24 h. After 3 days, the cells were treated
again with 1 ,UM Go6976 for 2 h and fresh medium was added.
After 4 days, the cells were detached by trypsinization (Trypsin
0.05%-EDTA 0.02%, Life Technologies) and used for subcellular
fractionation or for Western blot analysis.
Clonogenic surviving test
Four hundred cells were plated in tissue culture dishes, exposed to
1 ,UM G66976 for 2 h and then treated with increasing concentra-
tions of doxorubicin for 24 h. Medium was then removed and
fresh medium was added. After 3 days, the cells were exposed
again to G66976 and 4 days later the surviving colonies, grown in
drug-free medium, were counted.
Subcellular fractionation and PKC assay
Particulate, cytosolic and nuclear fractions were obtained as previ-
ously described (La Porta and Comolli, 1995). Briefly, the cells
were homogenized with buffer A containing 20 mM Tris-HCl,
pH 7.5, 2 mm EDTA, 0.5 mm EGTA, 5AM leupeptin, 0.15,tM
pepstatin A, 0.5 mM phenylmethylsulphonyl fluoride (PMSF) and
centrifuged in a minifuge at 14 000 r.p.m. for 15 min. The super-
natant was designated as the cytosolic fraction while the pellet was
resuspended in buffer A containing 1% Triton-XIOO and finally
centrifuged in aminifuge at 14 000 r.p.m. for 15 min. The resulting
supernatant was designated as the particulate fraction. Cytosolic
and particulate fractions were partially purified on DEAE-
Sepharose (Sigma, St. Louis, MO, USA) and PKC was eluted with
120 mm sodium chloride as previously described (La Porta and
Comolli, 1995). The nuclear fraction was obtained by homoge-
nizing the cells in buffer B containing 1.3M sucrose, 1 mM
magnesium chloride, 10 mm phosphate buffer, pH 6.8, 1 mM DDT,
1O jg ml-' leupeptin and 2 mm PMSF and the suspension was
I i
CH3 (CH2)2CN
Figure 1 Chemical structure of Go6976
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Figure 2 50 x 103 WT or DX LoVo cells were plated and treated with 1 ,UM
Go6976 for 2 h (time 0, arrowhead) and also 3 days later. The cells were
counted at time 0 up to 144 h. Control untreated cells were plated and
counted at the same times
layered over 2 ml buffer C solution and centrifuged in a minifuge
for 20 min at 14 000 r.p.m. The nuclei were counted and the purity
ofnuclearpreparation wasjudged by assaying 5'-nucleotidase as a
plasma membrane marker and lactate dehydrogenase as acytosolic
marker (La Porta and Comolli, 1995), contamination being less
then 2%. Finally, the nuclear extract was obtained from nuclei
resuspended in buffer E containing 20 mM Tris-HCl, pH 7.5, 2 mM
EDTA, 0.5% Triton-X100, 10 jig ml-' leupeptin and 2 mM PMSF
and sonicated in ice. Total fractions were obtained homogenizing
the cells in the buffer A containing 1% Triton-X100.
Particulate, cytosolic and nuclear fractions from murine brain
tissue were obtained following the same procedures.
Fractions were tested for c-PKC activity by measuring the
amountof32pincorporated into histone IIIS from [y-32P]ATP in the
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Figure 3 Particulate and cytosolic fractions (100 jig protein) of WT or DX
LoVo cells untreated and treated for 2 h with 1 gM Go6976 after plating the
cells and 3 days later were submitted on day 7 to 10% SDS-PAGE and then
transferred to nitrocellulose sheet overnight. The sheet was incubated with
2.5 jg ml-' of polyclonal anti-PKC-a antibody overnight. Peptide used to
raise the anti-PKC antibody was used in competition studies to demonstrate
the specificity of the polyclonal antibody. Particulate and cytosolic fractions
obtained from brain tissue were used as positive control
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Figure 4 400 WT or DX LoVo cells were exposed to 1 jiM Go6976 for 2 h
and then treated with increasing concentrations of doxorubicin (3, 10, 20, 30,
40, 50 and 80 ng ml-1 for WT and 100, 300, 500 and 1000 ng ml-1 for DX
cells) for 24 h. After 3 days, the cells were treated again with 1 jiM Go6976.
Four days later, the surviving colonies were counted. Control WT and DX
LoVo cells were submitted to increasing doxorubicin concentrations for 24 h,
then grown in drug-free medium and counted 7 days later
presence of phospholipids (phosphatidylserine and diolein) and
calcium (Martiny-Baron et al, 1993). Background activity was
measured with EGTA and in the absence of phospholipids and
calcium.
Western blot analysis
Immunoblot analysis was carried out on particulate, cytosolic and
total fractions mixed with 2x sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS-PAGE) buffer, then subjected to
Figure 5 Western blot analysis of P-glycoprotein in LoVo WT cell lines
untreated or treated with Go6976. One hundred micrograms was submitted
to 8% SDS-PAGE and then transferred to nitrocellulose overnight. The sheet
was incubated with 2.5 jg ml-1 polyclonal antibody anti-MDR overnight.
Peptide used to raise the anti-MDR antibody was used in competition studies
to demonstrate the specificity of the antibody
10% SDS-PAGE according to Laemmli (Laemmli, 1970) and then
transferred to nitrocellulose overnight (Towbin et al, 1979). After
blocking non-specific sites with blocking solution provided by
Boehringer Mannheim, the sheet was incubated overnight with
rabbit polyclonal antibodies (UBI, Lake Placid, NY, USA) recog-
nizing PKC-a isotype or P-glycoprotein and then detected with
peroxidase-labelled secondary antibody and the chemiluminescent
substrate luminol according to the manufacturer's instructions
(BM, Chemiluminescence Western blotting kit, Boehringer
Mannheim, Germany). Peptides used to raise the anti-PKC anti-
bodies were used in competition studies to demonstrate specificity
ofthe polyclonal antibodies. The molecular weight ofPKC-ax was
determined using BioRad (Segrate, Italy) standard proteins and
were in agreement with those reported by Wetsel et al (1992).
Equal loading of protein on the gel was verified by 10% SDS-
PAGE stained with Coomassie brilliant blue R250. Particulate,
cytosolic and nuclear fractions obtained from murine brain tissue
were used as positive control.
The results were analysed by densitometric analysis using an
ImageMaster software (Pharmacia, Uppsala, Sweden).
RESULTS
LoVo WT cells continuously exposed to doxorubicin acquire a
resistant phenotype (DX), and express higher levels of mdr-l
mRNA encoding for the P-glycoprotein (Grandi et al, 1986). WT
and DX LoVo cells express only PKC-a, beingPKC-P and -yunde-
tectable using Western blot analysis (data not shown) according to
Beck et al. (1996). To inhibit PKC-x for long periods, at least 7
days, an experimental protocol was considered. We tested different
concentrations of Go6976 and we used the lowerst concentration
able to inhibit significantly PKC-a activity (data not shown).
Moreover, with the purpose ofreducing the toxicity ofthe Go6976
and also of maintaining the PKC-a isoform inhibited for long
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Figure 6 Nuclear c-PKC activity expressed as pmol per min per 10: nuclei
in WT LoVo cells untreated or treated with 1 gM G66976 as described in
Figure 1. "'P< 0.001
periods. x-e treated the cells tx-ice %vith the inhibitor, once at the
berinning of the experiment and the second time at the middle of
the treatment on the 3rd dav. In fact. under such conditions. the
treatment % as not too toxic. the LoVo cells that received the
complete inhibitorv treatment shoxx ing at 144 h a sliaht decrease in
the proliferative capacity with respect to untreated cells (Figure 2:
U'T: 29%7. P<0.05: DX: 32%l. P < 0.05). A sirnificantlv decreased
actixitx in the particulate fraction occurred in both cell lines (Table
1: UT: 60% in treated cells w-ith respect to untreated cells. P<0.01:
DX: 52%S in treated cells with respect to untreated cells. P < 0.01).
In addition. an increased immunoblot signal for PKC-ac was found
in treated W'T and DX LoVo cells w-ith respect to untreated cells
(Fiaure 3).
Under such conditions. XXT cells receiving, the complete
inhibitors treatment and exposed to increasina concentrations of
doxorubicin (from 20 ng ml-' to 50 ng ml ') show-ed an enhanced
cell survixal w%ith respect to untreated cells (Figure 4). In fact. in
spite of the slight inhibition of the proliferative capacity in both
cell lines (Figure 2). LoVo WT cells treated with the selectixe
inhibitor Go6976 were susceptible to a higher doxorubicin
concentration (80 ng ml-'). Moreover. WT-treated cells showed an
increased P-glycoprotein expression (Figure 5). In contrast. DX
cells treated with the PKC inhibitor did not showv significant
changes with respect to untreated cells in the sunrixal of doxoru-
bicin exposure (Figure 4). and the lexel of P-glvcoprotein did not
show anv significant chance (data not shown).
We also analvsed the nuclear actix itv and expression ofPKC-ax.
the main PKC isoform expressed in these cells. in both cell lines
untreated or treated w-ith G66976. WT-treated cells showed a
sirnificant increase (P<0.01) of nuclear PKC-ot actixitx with
respect to untreated cells (Figure 6) w-ithout changes in its expres-
sion (Figure 7). In contrast. no significant nuclear activity and
expression was detected in untreated DX cells (Figure 7).
DISCUSSION
P-gl coprotein expression is commonl- obser-ed in MDR cell
lines. including LoVo DX cells (Grandi et al. 1986). Several lines
of evidence indicate that PKC regulates the activitx and/or the
expression of this protein. For example. solid tumours and
haemopoietic cell lines treated %vith phorbol 12-myristate 13-
acetate (PMA) or diacylglycerol increased the level ofboth mdr-J
and P-glycoprotein (Gupta et al. 1994). In greneral. PKC-at appears
Figure 7 Westem blot analysis of nuclear c-PKC-a isoform in WT and DX
LoVo cells untreated and treated with 1 gm G66976 as described in Figure 1.
One hundred micrograms of protein was subnmitted to 100o SDS-PAGE and
then transferred to nitrocellulose sheet ovemight. The sheet was incubated
with 2.5 pg mrn, anti-PKC-a antibody. Peptide used to raise the anti-PKC
antibody was used in competition studies to demonstrate the specficty of the
polycdonal antibody. Nuclear fraction obtained from brain tissue was used as
positive control
the most consistently implicated isoform. In fact. increased
expression of such isoenzymes has been reported in a number of
cell lines selected for resistance to sexeral anti-cancer agents.
includinc doxorubicin-resistant MCF-7 breast carcinoma cells
(Blobe et al. 1993). doxorubicin-. vinblastine- and colchicine-
resistant KB human epidermoid carcinoma cells (Davies et al.
1996) and in KB-A 10 cell lines (Posada et al. 1989b).
In this report. we has-e studied the effect of long-term inhibition
ofthe PKC-a isoform on the survival ofWT and DX LoVo cells to
increasing concentrations of doxorubicin. Treatment Axith the
specific PKC-oa and [I isoforms inhibitor. G66976 (Martins-
Baron et al. 1993). inhibited PKC-c activitv. the main PKC
isoform expressed in such cells (Drewx et al. 1994). Hoxxever. the
treatment with this PKC inhibitor induced an increased expression
of PKC-a in both cell lines. suggesting that the enhanced expres-
sion of specific PKC isoforms is not alw ay s direct exvidence of the
status of activation of the enzyme. In fact. under our conditions.
the cells might compensate for the reduced actix ity by increasing
the level of the enzyme. Moreoxer. such treatment induced a
significant increase in the survival of AT cells exposed to
increasing concentrations of doxorubicin and an increased P-
glxcoprotein expression. In contrast. it did not affect the sur-ivval
of DX cells that showed basically a higher drug resistance and
expressed P-glI-coprotein. Therefore. changes in PKC-a activits
did not modify the phenotype ofsuch cells. Recently. other authors
have studied long-term exposure to staurosporine analogues for 6
months. demonstrating that human lung A549 carcinoma cells
acquire a resistant phenotype which does not appear to involve
increased drug efflux (Gescher et al. 1997). Our results also indi-
cate the possible involvement of nuclear PKC-a in the acquisition
of a drug-resistant phenotype in WT cells. In fact. under these
conditions. such isoforms showed an increased activity possibly
affecting the expression of P-glycoprotein or of other multidruu-
related proteins. In connection with WI LoVo cells. MCF7 cells
resistant to doxorubicin showed a nuclear pool of PKC-x that
British Joumal ofCancer (1998) 78(10). 1283-1287
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probably maintained the drug resistant state of these cells (Lee et
al. 1992). In contrast. in DX cell lines we did not find any signifi-
cant expression ofsuch isoforms in the nucleus. c-PKC-a showing
a different subcellular distribution in DX LoVo with respect to
MCF-7 cell lines. Recently. other specific PKC inhibitors such as
bisindolylmaleimide and calphostin C blocked the activation of
NF-kB. suggesting a relationship between PKC activation and NF-
kB activation that might contribute to the expression of genes
involved in the resistant phenotype (Das and White. 1997). In
addition. the modulation ofother kinases downstream with respect
to PKC-a might be involved in the acquisition of the resistant
phenotype ofLoVo WT cells.
Taken together. ourresults indicate a relationship between PKC-
a inhibition. an increased nuclear activity of this isoform and the
acquisition of a resistant phenotype in LoVo WT cells. It is
tempting to speculate that overexpression of c-PKC-oa and the
long-term inhibition ofsuch isoforms induce a resistant phenotype
possibly through different mechanisms. In the first case. the
permanent high level of c-PKC-a is likely to induce the phos-
phorylation of P-glycoprotein. whereas in the second case the
long-term inhibition enhances the P-glycoprotein level. Therefore.
the hypothesis speculated by several authors that the selective inhi-
bition of PKC-a may chemosensitize tumour cefls to anti-cancer
therapy might not be correct. Recently. different concentrations of
doxorubicin induced apoptosis or oxidative DNA damage (Muller
et al. 1997). Work is in progress to analyse the intracellular role of
PKC-a with respect to the cytotoxic mechanism of doxorubicin
under the present conditions and also in other human cell lines.
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